The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Many Drug Companies Fail to Conduct Timely Safety Checks on Medicines after FDA Approval

Many Drug Companies Fail to Conduct Timely Safety Checks on Medicines after FDA Approval

September 22, 2017 • By Gene Emery

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—In the rush to approve new medicines, the U.S. Food and Drug Administration often requires drug companies to study possible side effects and alternative doses for medicines once they hit the broader market.

You Might Also Like
  • FDA Drug Labeling, Approval Process Help Minimize Lawsuits Against Pharmaceutical Companies
  • Heart Safety Clouds Hopes for Amgen, UCB Bone Drug Approval
  • FDA Reviewers Question Safety of AstraZeneca’s Gout Drug
Also By This Author
  • Pricey Arthritis Drug Effective in Small Fraction of Ulcerative Colitis Cases

A September 20 online analysis in the New England Journal of Medicine concludes that, in many cases, that’s not being done.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Steven Woloshin of the Dartmouth Institute for Health Policy and Clinical Practice in Lebanon, New Hampshire, and colleagues looked at federal records and found that among the 614 studies mandated in 2009 and 2010, 20% were never started and 9 percent have been delayed.

“When drugs are approved, the trials are usually small and short-term, and some side effects may not emerge until the post-marketing phase,” Woloshin told Reuters Health in a telephone interview. “The problem is, the faster you get them on the market, the more open questions there are” about their safety or the best dose.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In a response published in the Journal, the FDA said that by its tally, 88% of all postmarketing requirements – not just those mandated in 2009 and 2010 – “were progressing according to their original schedules” as of the 2015 fiscal year.

One of four drug companies contacted by Reuters Health provided evidence that the information about its post-approval registry reported by the Woloshin team is inaccurate.

With President Donald Trump vowing to further speed the FDA approval process, “Drug approval is likely to become increasingly rapid and rely on looser evidence standards,” the Woloshin team writes in its report. “It will be crucial to ensure that the important questions that are unanswered at the time of approval are resolved as quickly as possible, too.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

One example of missed deadlines is Indivior’s Suboxone, a combination of buprenorphine and naloxone used to treat opioid dependence. The FDA wanted to know if it caused a specific problem with the heart.

“The sponsor was given more than 1 year to submit the trial protocol and 5 years to complete the trial,” the study authors write. “Nevertheless, as of July 2017, the final protocol had apparently not been submitted.”

And when Novartis’ $72,000-a-year multiple sclerosis treatment Gilenya (fingolimod) was approved, the FDA told the company to test a lower daily dose.

“Sometimes a lower dose may be as effective but have fewer side effects,” Woloshin explained.

Yet “more than 6 years after approval, the trial had not been completed because of recruitment difficulties despite the manufacturer reporting $2.8 billion in sales,” the researchers write.

Pages: 1 2 | Single Page

Filed Under: Drug Updates, Ethics Tagged With: Dartmouth Institute for Health Policy and Clinical Practice, drug companies safety checks, FDA approval, Gilenya (fingolimod), Indivior's Suboxone, U.S. Food and Drug Administration

You Might Also Like:
  • FDA Drug Labeling, Approval Process Help Minimize Lawsuits Against Pharmaceutical Companies
  • Heart Safety Clouds Hopes for Amgen, UCB Bone Drug Approval
  • FDA Reviewers Question Safety of AstraZeneca’s Gout Drug
  • U.S. FDA Panel Votes Against Approval of Arthritis Drug Sirukumab

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)